Plastic Degradation ™

THE COMPANY

We are humans focused
on engineering non-model
organisms for
unconventional
applications.

Plastic isn’t just a me problem. Or a you problem. It’s an everywhere, everything, all-the-time problem. And Breaking is building the fix for that.

Let’s be clear, plastic is a true marvel of invention and industry. From transportation to healthcare, it’s played a role in rapidly upgrading the human condition.

Let’s be clear, plastic is a true marvel of invention and industry. From transportation to healthcare, it’s played a role in rapidly upgrading the human condition.

But it’s
gone
too far.

With single-use plastics lining grocery store shelves, giant laundry detergent containers getting tossed in the garbage by the millions, and more, the utility is being outweighed by the sheer amount of resilient, nearly-everlasting garbage itself. It’s a mess. And it’s messing up the ecosystems that keep Earth in a healthy balance.

And if our planet isn’t safe, then nothing that lives on our planet is safe. That includes plants, animals, me and you. So maybe it is a me and you problem. But that’s why Breaking is here to build a better future.

"We have entered an era in which our environments and bodies are at risk to micro and nano particles of polymers (plastics) that we once trusted. We have also entered an age of exponential technologies in which can see and seek the nuances and continua of polymers. Harmful-to-helpful is not neatly natural vs synthetic; it depends on size, shape and location of the polymer particles. For example, polyethylene has the same set of bonds as beeswax, just longer. We are “Breaking” these and reusing the parts in beneficial reconfigurations."

George

Church, Ph.D.

"We have entered an era in which our environments and bodies are at risk to micro and nano particles of polymers (plastics) that we once trusted. We have also entered an age of exponential technologies in which can see and seek the nuances and continua of polymers. Harmful-to-helpful is not neatly natural vs synthetic; it depends on size, shape and location of the polymer particles. For example, polyethylene has the same set of bonds as beeswax, just longer. We are “Breaking” these and reusing the parts in beneficial reconfigurations."

Breaking

Down Every

Type Of

Plastic

Leadership

Core Team

We are humans focused on engineering non-model organisms for unconventional applications.

Sukanya
Punthambaker, PH.D.

Vaskar
Gnyawali, Ph.D.

Bryan
Mejia-Sosa

Adnan
Syed, Ph.D

Yuki
Sugimoto, Ph.D

Heidi
Schindel, Ph.D.

FOCUSING

Scientific Advisors

Providing guidance and expertise on the scientific aspects of plastic degradation processes.

John
Warner, PH.D

Beth
Shapiro, PH.D

Jon
Kaneshiro

Founding Team

Founders

We are humans focused on engineering non-model organisms for unconventional applications.

Sukanya
Punthambaker, PH.D.

Vaskar
Gnyawali, Ph.D.

George
Church, Ph.D.

Donald
Ingber, M.D., Ph.D.

Alba
Tull

Kent
Wakeford

Ben
Lamm

"We are excited to see how Colossal Biosciences has enabled our novel discovery to break away from its competitors in the plastic remediation space by developing a bioinspired technology that can degrade many types of plastics that are threatening our environment. This can be accomplished without pretreatment and the breakdown products could be used to produce other valuable materials and commodities. This is what sets Breaking apart from the field."

Donald

Ingber, M.D., Ph.D.

Ingber

Co-founder and Founding Director of the Wyss Institute at Harvard University, Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children's Hospital, and Hansjorg Wyss Professor of Bioinspired Engineering at Harvard John A. Paulson School of Engineering & Applied Sciences

"We are excited to see how Colossal Biosciences has enabled our novel discovery to break away from its competitors in the plastic remediation space by developing a bioinspired technology that can degrade many types of plastics that are threatening our environment. This can be accomplished without pretreatment and the breakdown products could be used to produce other valuable materials and commodities. This is what sets Breaking apart from the field."

Researching.

Experimenting.

Caring.

Focusing.

Targeting.

Digesting.

Decomposing.

Recycling.

Reformulating.

Reviving.

Rebuilding.

Learn More

We are
breaking
stereotypes

Learn More

Company Page

"Breaking is solving one of the biggest problems on our planet. They are using the natural world as inspiration and layering on cutting edge technology to transform how we break down plastics. This is going to be one of the biggest breakthroughs of the decade and I'm excited to be part of it."

Jim

Kim

Founding Member & General Partner at Builders VC

"Breaking is solving one of the biggest problems on our planet. They are using the natural world as inspiration and layering on cutting edge technology to transform how we break down plastics. This is going to be one of the biggest breakthroughs of the decade and I'm excited to be part of it."

Partners

Bringing together cutting-edge science and industry leaders to transform the landscape of plastic pollution. Tackling a macro problem with a micro solution.

The science of genetics. The business of discovery.

01

Colossal Biosciences is the world’s first and only de-extinction company. The efforts at Colossal have helped create revolutionary spinoff innovations, form new companies and expand the boundaries of what is possible.

Using our advancements in cutting-edge science and groundbreaking technology, Colossal maintains a commitment to responsibility, ethics, conservation, exploration and the restoration of our planet’s natural biodiversity. With every breakthrough, Colossal moves closer to restoring our Earth to a healthier state today—and safeguarding it for future generations to come.

For Biologically Inspired Engineering

02

The Wyss Institute at Harvard University is a research and development engine for disruptive innovation—powered by bioinspired technologies with visionary people at its heart.

We leverage recent insights into how nature builds, controls and manufactures. By emulating its biological principles of self assembly, organization and regulation, we are developing solutions for healthcare, energy, architecture, robotics and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.

Church Lab / Department of Genetics at Harvard

03

The Church Lab at Harvard University works on research projects that are distributed in diverse areas of modern biology, such as developmental biology, neurobiology, info processing, medical genetics, genomics, gene therapy, diagnostics, chemistry & bioengineering, space biology & space genetics, and ecosystems.

Research and technology developments at the Church Lab have impacted or made direct contributions to nearly all next-generation sequencing (NGS) methods and companies.

Current
Investors

tackling plastic waste, recognizing its environmental impact and potential for innovative solutions

Investors who prioritize sustainability

"Just as compostable materials represent humanity making our goods more palatable to nature, Breaking represents a jumpstart in the ability of nature to find materials like plastic, palatable."

Tom

Chi

Founding Partner at One Ventures

"Just as compostable materials represent humanity making our goods more palatable to nature, Breaking represents a jumpstart in the ability of nature to find materials like plastic, palatable."

Article

01/02/24

Lorem ipsum dolor sit amet, consectetur adipiscing elit

Article

01/02/24

Lorem ipsum dolor sit amet, consectetur adipiscing elit

Article

01/02/24

Lorem ipsum dolor sit amet, consectetur adipiscing elit

CLOSE

Sukanya
Punthambaker, PH.D.

Co-Founder and CEO

Sukanya Punthambaker, Ph.D., has over two decades of experience in life sciences research and biotechnology. Previously, she worked extensively with Dr. George Church at Harvard Medical School and the Wyss Institute, for a number of years on several technology development projects in synthetic biology, sequencing and protein engineering. She has held leadership roles having taught neuroscience to over 100 undergraduate students, while at the University of Michigan, collaborated with multiple scientists and teams at Harvard to take an idea to completion in the form of scientific publications and commercializations, and demonstrated multidisciplinary expertise working on a range of projects from DNA nanotechnology to genetically engineered microbes for sustainability.

She has received several highly prestigious awards including the Department of Biotechnology - Junior Research Fellowship, India, the Outstanding Graduate Student Instructor Award and the Okkelberg Award to an exceptional senior graduate student, both from the University of Michigan. She has co-authored impactful publications in reputed peer reviewed journals such as Nature, Science, NAR, PNAS, etc. She earned her PhD in molecular biology from University of Michigan Ann Arbor, MS in biotechnology and BS in microbiology, both from India.

Vaskar
Gnyawali, Ph.D.

Co-Founder and CSO

Vaskar Gnyawali, Ph.D. brings over 13 years of versatile engineering experience to his role as Chief Science Officer (CSO). His expertise spans various engineering domains, including computer engineering, microsystems, biomechanical engineering, and most recently, microbial engineering. Previously, at the Wyss Institute for Biologically Inspired Engineering at Harvard University, he applied his expertise in solving complex biological problems, such as developing a novel encapsulation technology for the enhanced delivery of biologic drugs and smart food ingredients, under the mentorship of Prof. Donald Ingber.

Vaskar has garnered numerous accolades for his academic and entrepreneurial prowess, including the prestigious Governor General’s Gold Medal and Doctoral Completion Award for his outstanding achievements during his doctoral studies, and a leadership scholarship for his master’s degree. Furthermore, he has made significant contributions to impactful publications and inventions.

Vaskar earned his bachelor's degree in Computer Engineering from the Institute of Engineering at Tribhuvan University in Nepal. He continued his academic journey by obtaining a master's degree from the University of Freiburg in Germany. Later, he pursued his doctoral studies at Ryerson University (Toronto Metropolitan University) in Toronto, Canada, culminating in the attainment of his doctoral degree.

George
Church

Co-Founder

George leads Synthetic Biology at the Wyss Institute, where he oversees the directed evolution of molecules, polymers, and whole genomes to create new tools with applications in regenerative medicine and bio-production of chemicals. Among his recent work at the Wyss is development of a technology for synthesizing whole genes, and engineering whole genomes, far faster, more accurate, and less costly than current methods. George is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine. In 1984, he developed the first direct genomic sequencing method, which resulted in the first genome sequence (the human pathogen, H. pylori). He helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. George invented the broadly applied concepts of molecular multiplexing and tags, homologous recombination methods, and array DNA synthesizers. His many innovations have been the basis for a number of companies including Editas (Gene therapy); Gen9bio (Synthetic DNA); and Veritas Genetics (full human genome sequencing).

George is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Technology Center and Director of the National Institutes of Health Center of Excellence in Genomic Science. He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute and election to the National Academy of Sciences and Engineering.

Donald
Ingber, M.D., Ph.D.

Co-Founder

Donald E. Ingber, M.D., Ph.D., is the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital, and the Hansjörg Wyss Professor of Bioinspired Engineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. He received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University.

Ingber is a pioneer in the field of biologically inspired engineering, and at the Wyss Institute, he currently leads scientific and engineering teams that cross a broad range of disciplines to develop breakthrough bio-inspired technologies to advance healthcare and to improve sustainability. His work has led to major advances in mechanobiology, cell structure, tumor angiogenesis, tissue engineering, systems biology, nanobiotechnology and translational medicine. Through his work, Ingber also has helped to break down boundaries between science, art, and design.

Ingber has authored more than 500 publications and 165 patents, founded 5 companies, and has presented 550 plenary presentations and invited lectures world-wide. He is a member of the National Academy of Engineering, National Academy of Medicine, National Academy of Inventors, American Institute for Medical and Biological Engineering, and the American Academy of Arts and Sciences. He was named one of the Top 20 Translational Researchers world-wide in 2012 and 2020 (Nature Biotechnology), a Leading Global Thinker of 2015 (Foreign Policy magazine), and has received numerous other honors in a broad range of disciplines, including the Robert A. Pritzker Award and the Shu Chien Award (Biomedical Engineering Society), Rous Whipple Award (American Society for Investigative Pathology), Lifetime Achievement Award (Society of In Vitro Biology), Leading Edge Award (Society of Toxicology), Founders Award (Biophysical Society), Department of Defense Breast Cancer Innovator Award, and Wilbur Cross Medal from Yale University.

Ingber has made great strides in translating his innovations into commercial products and many are now either in clinical trials or currently being sold. Examples of technologies Ingber has developed include therapeutics for cancer and pandemic viruses; micropatterned culture substrate research tools; a dialysis-like sepsis therapeutic device that clears blood of pathogens and inflammatory toxins along with a companion diagnostic; an anticoagulant surface coating for medical devices that replaces the need for dangerous blood-thinning drugs; a shear stress-activated nanotherapeutic that targets clot-busting drugs and vasodilators to sites of vascular occlusion; low cost nasopharyngeal swabs and highly sensitive multiplexed electrochemical sensors for COVID-19 diagnostics; and Human Organ Chips lined by living human cells that are being used to replace animal testing for drug development and personalized medicine. Ingber’s Organ Chip technology was named one of the Top 10 Emerging Technologies by the World Economic Forum and Design of the Year by the London Design Museum. It was also acquired by the Museum of Modern Art (MoMA) in New York City for its permanent design collection.

Bryan
Mejia-Sosa

Senior Scientist

Bryan Mejia-Sosa is a multidisciplinary scientist who earned his Bachelor's degree in Biological Engineering from MIT where his interest in synthetic biology and sustainable development first led him to study and engineer microbes for the production of terpenes as jet fuel precursors. He later graduated from the University of Illinois at Urbana-Champaign with a Master's in Chemical and Biomolecular Engineering where he modified oleaginous yeast for the production of value-added fatty acids. Since then, he's modified filamentous fungi and bacteria for various industrial applications, and now brings his diverse engineering background to Breaking.

Alba
Tull

Co-Founder

Alba Tull is a world-renowned storyteller, environmental activist, and philanthropist. She is currently on the board of Pittsburgh’s Carnegie Science Center, The Jackie Robinson Foundation, and is a member of Carnegie Mellon University’s Highlands Circle.

Kent
Wakeford

Kent Wakeford is co-founder and co-CEO of Form Bio, a leading computational biology platform with a mission of empowering scientists to discover and manufacture therapeutics for genetic diseases. He is a co-founder and former COO of Colossal Biosciences which partnered with Harvard and the George Church Lab to apply advancements in synthetic biology to loss of biodiversity.

Prior, Kent co-founded multiple technology and data science companies and has created over $3B in shareholder value, including one publicly traded company (IAS: NASDAQ). He is the co-inventor on over 85 patents in software and applied data science.

Benn
Lamm

Co-Founder

Ben Lamm is the co-founder and CEO of Colossal. Ben is a serial technology entrepreneur driven to solve the most complex challenges facing our planet. For over a decade, Ben has built disruptive businesses that future-proof our world. In addition to leading and growing his own companies, he is passionate about emerging technology, science, space and climate change. Active in angel investing, incubators and startup communities, Ben invests in software and emerging tech, and is deeply engaged in the technology, defense and climate change communities.

Prior to Colossal, Ben served as the founder and CEO to a number of companies, including Hypergiant, an enterprise AI software company focused on critical infrastructure, space and defense acquired by Trive Capital; Conversable, the leading conversational intelligence platform that helps brands reach customers through automated experiences acquired by LivePerson; and Chaotic Moon, a global creative technology powerhouse acquired by Accenture. Ben was also the co-founder of Team Chaos, a consumer gaming company acquired by Zynga.

Ben is a fellow of the Explorer’s Club, whose mission is to promote the scientific exploration of land, sea, air, and space by supporting research and education in the physical, natural and biological sciences. He also serves as a Scientific Advisory Board member on the Planetary Society and sits on the Advisory Board for the Arch Mission. Ben has appeared as a thought leader in many publications, including the Wall Street Journal, New York Times, Forbes, Entrepreneur, Wired, TechCrunch, VentureBeat, and Newsweek on topics such as innovation, technology and entrepreneurship.

John
Warner, PH.D

Scientific Advisor

John Warner is one of the founders in the field of green chemistry. He wrote the book that provides the definition and 12 principles of green chemistry with Paul Anastas in 1998. As an industrial chemist, he has over 350 patents and has worked with hundreds of companies worldwide. He received the Perkin Medal in 2014 from The Society of Industrial Chemistry.

As an academic, he was a tenured full professor of chemistry and a tenured full professor of plastics engineering at the University of Massachusetts where he started the world’s first PhD program in Green Chemistry. He has over 120 publications in synthetic methodologies, non covalent derivatization, polymer photochemistry, metal oxide semiconductors and green chemistry. In 2022 he received the August Wilhelm von Hofmann Medal from the German Chemical Society and in 2004 the Presidential Award for excellence in science mentoring (PAESMEM) from the US National Science Foundation (NSF) and President George W Bush.

As an inventor, John’s inventions have led to the founding of many companies in the fields of photovoltaics, neurochemistry, construction materials and cosmetics. In 2016 he received the Lemelson Invention Ambassadorship from the Lemelson Foundation and the American Association for the Advancement of the Sciences (AAAS). John is a member of the Club of Rome, Distinguished Professor of Green Chemistry at Monash University in Australia, Distinguished Professor of Chemistry at Chulalongkorn University in Thailand, and Honorary Professor of Chemistry at the Technical University of Berlin where they have named the “John Warner Center for Start Ups in Green Chemistry.” John currently serves as President and CEO of The Technology Greenhouse.

Beth
Shapiro, PH.D

Scientific Advisor

Beth Shapiro is an evolutionary biologist who specializes in the genetics of ice age animals and plants. A pioneer in the scientific field called “ancient DNA,” Beth has traveled extensively in the Arctic regions of Alaska, Siberia, and Canada collecting bones and other remains of long-dead creatures including mammoths, giant bears, and extinct camels and horses. Using DNA sequences extracted from these remains, Beth’s work aims to better understand how the distribution and abundance of species changed in response to major climate changes in the past, and why some species and communities are more resilient than others, with a goal to help develop strategies for conservation of endangered species and ecosystems today. Prior to joining Colossal as Chief Science Officer, Beth was a Professor and Director of the Paleogenomics Laboratory at the University of California Santa Cruz and an Investigator with the Howard Hughes Medical Institute. Beth is highly acclaimed for her research; she has been named a Searle Scholar, Packard Fellow, National Geographic Explorer, and MacArthur Fellow, and is an elected Fellow of both the American Association for the Advancement of Science and the prestigious American Academy of Arts & Sciences. She is also an award-winning popular science author and communicator whose books “How to Clone a Mammoth: The Science of De-extinction” (Princeton University Press 2015, 2020) and “Life As We Made It” (Basic Books 2021) explore how humans have been manipulating life on Earth for as long as we have existed and the potential of extending this to bring extinct species back to life.

Jon Kaneshiro

Scientific Advisor

Jon Kaneshiro is Vice President of Oahu Waste Services, Inc., Hawaii's largest waste hauling and recycling company. Jon oversees OWS and its subsidiaries' investments and strategic initiatives across their recycling and composting operations, real estate holdings, and expansion efforts. Prior, Jon held algorithm development and strategy positions in quantitative finance and technology firms.

Jon currently serves on the board of the Honolulu Board of Water Supply, the Island of Oahu's municipal water system. Jon has a bachelor's degree in civil and environmental engineering from Loyola Marymount University and a master's degree in environmental engineering from Massachusetts Institute of Technology.

Adnan Syed, Ph.D

Senior Scientist

Adnan spent 14 years at Harvard and the University of Michigan bridging ecological and genetic mechanisms of bacterial community formation. He is a holistic microbiologist skilled in assay development and high-throughput screening. Adnan is passionate about using biology to clean the world. Outside of the lab, Adnan loves to travel and share his wonder of the natural world with his kids.

Yuki
Sugimoto, Ph.D.

Yuki Sugimoto was born and raised in Japan. His academic journey led to earning a Ph.D in Natural Product Chemistry. Throughout his research, Yuki explored the intricate world of microbial metabolites. Now, with a focus on microbial engineering, he is dedicated to uncovering the remarkable abilities of microbes in order to solve environmental challenges.

Heidi
Schindel, Ph.D.

Sr. Bioinformatician

Heidi Schindel is a computational biologist specializing in applying multi-omics and AI/ML approaches to optimize non-model microbe engineering and scale-up efforts. She earned a PhD in Biochemistry from Indiana University, where she combined computational and lab techniques to characterize a novel bacterial microcompartment and multiple regulatory systems in purple photosynthetic bacteria. She then pursued a postdoc at Oak Ridge National Lab developing genetic tools for metabolic engineering of multiple non-model microbes as part of waste-to-fuels projects within the DOE Center for Bioenergy Innovation and Agile BioFoundry. She has since worked at climate-tech companies utilizing synthetic biology and computational approaches to help develop carbon-neutral cement (Biomason) and convert greenhouse gas emissions to useful chemicals (LanzaTech). Her industrial experience ranges from initial bacterial domestication and engineering to optimizing performance throughout the scale-up process. She is passionate about harnessing the potential of microbes to mitigate the effects of climate change and pollution and excited for the opportunity to be a part of Breaking.